Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00

Harrow (NASDAQ:HROW) had its target price decreased by equities research analysts at Cantor Fitzgerald from $94.00 to $91.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 151.59% from the company’s current price.

Several other analysts also recently weighed in on the company. William Blair restated an “outperform” rating on shares of Harrow in a report on Tuesday. Zacks Research downgraded shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 2nd. HC Wainwright boosted their price target on shares of Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Finally, LADENBURG THALM/SH SH lifted their price objective on shares of Harrow from $64.00 to $66.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Eight research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat.com, Harrow has a consensus rating of “Moderate Buy” and a consensus target price of $71.14.

Harrow Stock Performance

Harrow stock opened at $36.17 on Wednesday. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.52 and a current ratio of 2.20. The company has a market capitalization of $1.35 billion, a PE ratio of -212.75 and a beta of 0.05. The company has a 50 day moving average price of $47.92 and a 200-day moving average price of $43.71. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $54.85.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.23). The firm had revenue of $89.09 million during the quarter, compared to the consensus estimate of $88.42 million. Harrow had a positive return on equity of 36.51% and a negative net margin of 1.89%. As a group, equities analysts forecast that Harrow will post -0.53 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HROW. University of Texas Texas AM Investment Management Co. purchased a new stake in Harrow during the fourth quarter valued at approximately $26,000. Raymond James Financial Inc. purchased a new stake in shares of Harrow during the 2nd quarter valued at $48,000. SBI Securities Co. Ltd. lifted its holdings in shares of Harrow by 393.5% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,061 shares of the company’s stock valued at $52,000 after purchasing an additional 846 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of Harrow in the 3rd quarter worth $83,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Harrow by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after buying an additional 369 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Key Headlines Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: HC Wainwright kept a Buy rating and raised its price target to $70, signaling continued upside from that shop despite recent volatility. H.C. Wainwright PT Raised
• Positive Sentiment: Company reported record 2025 results and set a 2026 outlook, underscoring underlying revenue momentum that management says supports growth investments. Record 2025 Results
• Positive Sentiment: Management outlined a $350M–$365M 2026 revenue goal tied to salesforce expansion and pipeline progress — a constructive guide for top-line growth if execution holds. 2026 Revenue Goal
• Neutral Sentiment: Cantor Fitzgerald trimmed its price target slightly (from $94 to $91) but remains Overweight, leaving a large implied upside from current levels — mixed signal on conviction. Cantor Fitzgerald PT Change
• Neutral Sentiment: Management will present at the Leerink Global Healthcare Conference (Mar 10), giving investors another opportunity for management commentary and Q&A. Leerink Presentation
• Negative Sentiment: Zacks Research downgraded Harrow from Hold to Strong Sell, increasing bearish analyst pressure and likely contributing to near-term selling. Zacks Downgrade Coverage
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS forecasts (Q3: $0.29 → $0.20; Q4: $0.51 → $0.40), reflecting weaker near-term profit expectations even while the firm keeps a Buy rating. HC Wainwright Estimate Cuts
• Negative Sentiment: Investors reacted to a disappointing Q4 EPS print (reported EPS well below consensus), margin pressure, and warnings about higher S&M and interest expense; analysts and outlets highlighted valuation and leverage concerns. Coverage and analyses explain the post-earnings selloff. Earnings Transcript SA Analysis Shares Gap Down

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.